Mirror-Image Packing Provides a Molecular Basis for the Nanomolar Equipotency of Enantiomers of an Experimental Herbicide by Bisson, C. et al.
German Edition: DOI: 10.1002/ange.201607185Inhibitors
International Edition: DOI: 10.1002/anie.201607185
Mirror-Image Packing Provides a Molecular Basis for the Nanomolar
Equipotency of Enantiomers of an Experimental Herbicide
Claudine Bisson, K. Linda Britton, Svetlana E. Sedelnikova, H. Fiona Rodgers,
Thomas C. Eadsforth, Russell C. Viner, Tim R. Hawkes, Patrick J. Baker,* and David W. Rice*
Dedicated to the memory of Linda Britton
Abstract: Programs of drug discovery generally exploit one
enantiomer of a chiral compound for lead development
following the principle that enantiomer recognition is central
to biological specificity. However, chiral promiscuity has been
identified for a number of enzyme families, which have shown
that mirror-image packing can enable opposite enantiomers to
be accommodated in an enzymeQs active site. Reported here is
a series of crystallographic studies of complexes between an
enzyme and a potent experimental herbicide whose chiral
center forms an essential part of the inhibitor pharmacophore.
Initial studies with a racemate at 1.85 c resolution failed to
identify the chirality of the bound inhibitor, however, by
extending the resolution to 1.1 c and by analyzing high-
resolution complexes with the enantiopure compounds, we
determined that both enantiomers make equivalent pseudo-
symmetric interactions in the active site, thus mimicking an
achiral reaction intermediate.
The chiral nature of the active site of proteins generally gives
rise to the differential recognition of chiral substrates and
inhibitors. As a result, during programs of drug development,
an enzymeQs stereochemical preferences can be exploited to
achieve target selectivity and reduce the risk of toxicity.[2]
Although a chirally pure compound is often the desired
product of such schemes, the early stages of both pharma-
ceutical and agrochemical inhibitor development typically
start from synthetic racemates, which are often easier and
more cost effective to synthesize than a specific enantiomer
(see Ref. [2, 3] and references therein). The program of
herbicide development described herein aims to identify
inhibitors of imidazoleglycerolphosphate-dehydratase
(IGPD; EC 4.2.1.19), an enzyme of histidine biosynthesis in
plants and microorganisms. This enzyme catalyzes the
manganese(II)-dependent dehydration of (2R,3S)-2,3-dihy-
droxy-3-(1H-imidazol-5-yl)propyl dihydrogen phosphate
(2R,3S-IGP) to 3-(1H-Imidazol-4-yl)-2-oxopropyl dihydro-
gen phosphate (IAP; Figure 1).[4] IGPD shows strict enantio-
selectivity for its substrate, with the other three diastereoiso-
mers of IGP acting as competitive inhibitors of the enzyme,[5]
thus indicating that the active site shows some flexibility to
accommodate inverted chiral centers. Previous studies have
shown that IGPD is inhibited by triazolylphosphonates,
whose potency is based on mimicking key reaction inter-
mediates.[6] In this paper we describe work on the lead
compound, 2-hydroxy-3-(1,2,4-triazol-1-yl) propylphospho-
Figure 1. A schematic diagram outlining the reaction mechanism of
IGPD and showing the chemical structure of C348. Backbone carbon
atoms of C348 and the diazafulvene intermediate are numbered 1–3.
The chiral center of C348 is at C2.
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nate (C348 ; Figure 1) and present a series of structures of
IGPD, from Arabidopsis thaliana, complexed with a synthetic
racemate of C348 and with the enantiopure compounds. The
structural data show that both the (R)- and (S)-C348 make
equivalent interactions with the active site of IGPD and bind
with mirror-image packing. Data from both in vivo and
in vitro assays further shows that both enantiomers are
equipotent nanomolar inhibitors of the enzyme. By compar-
ing our enzyme/inhibitor complexes with that of structures of
IGPD complexed with the substrate, 2R,3S-IGP, we provide
a molecular explanation of this finding.
Crystals of a DN construct of IGPD isoform 2 from
Arabidopsis thaliana (At DN IGPD2 construct A; see
Supporting Information for experimental methods) were
grown in the presence of a racemate of C348 and the
structure of the enzyme/inhibitor complex was determined to
1.85c resolution. The resulting electron density showed clear
evidence for the ordering of the C-loop of IGPD2 (residues
193–206; see Figure S1 in the Supporting Information), with
the enzyme adopting the same closed conformation as seen in
the previously determined structure of an inactive mutant
(E21Q) of At IGPD2 with its substrate, IGP (PDB: 4MU4).[7]
Difference density for C348 could be identified within the
active site and the triazole ring could be modelled between
the two manganese ions with the N2 and N4 atoms forming
ligands to Mn1 and Mn2, respectively. The C348 C2@OH
group acts as an additional ligand to Mn1 and the phospho-
nate group is bound in a positively charged pocket, sur-
rounded by the side chains of R99, R121, K177, S199, and
K201, and by water-mediated hydrogen bonds to Q51 and
H55. However, despite the 1.85c resolution of the data,
there was a lack of electron density around C3 of the inhibitor
(see Figure S2a). And, as a result, whilst the major functional
groups of the inhibitor could be identified, the chirality of the
bound ligand was uncertain.
A shorter DN construct of IGPD2 (At DN IGPD2
construct B) yielded better quality diffracting crystals and
produced a structure of the IGPD2/C348 complex at 1.1c
resolution (PDB: 5EKW; Table 1). However, as with the
electron density for C348 in the 1.85c structure, the density
at 1.1 c resolution was also weak around C3. Nevertheless,
a small peak could be observed in the map around C3 when
contoured at 1 s, the position of which was consistent with the
binding of the (S)-C348 (see Figure S2b). Refinement of this
structure using tight geometric restraints revealed further
difference features, indicating a second position for the
inhibitor, which, from the geometry, could only be interpreted
as resulting from the binding of the (R)-C348 (see Fig-
ure S2c,d). This finding indicated that in the crystal, the active
sites of some of the enzyme molecules were occupied by (S)-
C348 and others were occupied by (R)-C348. Subsequent
refinement of this structure with occupancies of 0.6 and 0.4
for the (S)- and (R)-C348, respectively, produced a model
which fully explained the electron density, thus indicating that
both enantiomers of C348 were bound to an essentially
invariant enzyme structure.
Table 1: Data collection and refinement statistics.
At IGPD2 +
racemate C348
PDB: 5EKW
At IGPD2 +
(R)-C348
PDB: 5ELW
At IGPD2 +
(S)-C348
PDB: 5EL9
Pf IGPD +
(R)-C348
PDB: 5DNX
Pf IGPD +
(S)-C348
PDB: 5DNL
Data collection:
Wavelength [b] 0.95070 0.98020 0.97960 0.9794 0.9794
Space group P432 P432 P432 I422 I422
Cell dimensions; a, b, c [b] 112.9, 112.9, 112.9 112.6, 112.6, 112.6 112.6, 112.6, 112.6 140.4, 140.4, 136.7 141.3, 141.3, 137.4
Resolution [b] 35.7–1.1
(1.12–1.1)
45.96–1.36
(1.4–1.36)
45.98–1.1
(1.13–1.1)
48.98–1.8
(1.85–1.8)
49.25–1.53
(1.57–1.53)
Total observations[c] 1221822 (144649) 474417 (25277) 1625442 (48528) 1030031 (74677) 284672 (34864)
Unique observations[c] 99289 (14237) 52156 (3369) 98751 (6973) 63077 (4586) 54525 (7257)
Rmerge
[a,c] 0.082 (0.676) 0.068 (0.66) 0.063 (0.650) 0.118 (1.006) 0.080 (0.688)
Rpim
[b,c] 0.025 (0.175) 0.026 (0.271) 0.017 (0.275) 0.030 (0.257) 0.039 (0.141)
I/sI[c] 15.1 (2.2) 23.8 (2.8) 28.0 (2.9) 22.1 (4.6) 18.1 (4.1)
Completeness (%)[c] 99.5 (98.3) 99 (89.1) 99.6 (96.8) 100 (100) 100 (100)
Redundancy[c] 10.6 (5.1) 9.1 (7.5) 16.5 (7.0) 16.3 (16.3) 13.1 (13.2)
Refinement:
Rwork/Rfree 12.3/13.7 11.7/13.1 11.4/12.9 13.1/15.8 13.5/14.9
No. Atoms:
Protein 1569 1554 1607 4195 4196
Ligand/ions 78 32 52 45 45
Water 235 204 207 322 476
B-factors:
Protein 13.5 10.3 11.7 22.2 19.0
Ligand/ions 13.0 17.2 12.0 15.0 12.35
Water 26.8 23.1 27.5 29.0 27.6
RMS deviations:
Bond lengths [b] 0.01 0.01 0.01 0.01 0.09
Bond angles [8] 1.79 1.59 1.73 1.51 1.47
[a] Rmerge=ShklSi j Ii@Im j /ShklSiIi. [b] Rpim=Shkl/n@1Si=1 j Ii@Im j /ShklSiIi, where Ii and Im are the observed intensity and mean intensity of related
reflections, respectively. [c] Values within parentheses are for data in the high-resolution shell.
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To confirm that both enantiomers of C348 bind to IGPD2,
and to improve our interpretation of the mixed structure, we
resolved the C348 racemate by HPLC to greater than 98%
enantiopurity. The binding affinities for the enantiopure
compounds, (S)- and (R)-C348, against At DN IGPD2
(construct B) were measured by an in vitro enzyme assay
and gave apparent Ki values of (25: 3) and (15: 5) nm,
respectively (Figure 2a; see Figure S3). Glasshouse spray
studies, comparing the herbicidal properties of the two
enantiomers and the racemate, showed they all exhibited
similar efficacy in terms of the spray rate (kg/Ha) necessary to
cause 50% damage (as visually assessed; see Figure S4).
Whilst we had initially expected that the two enantiomers
would have quite different binding affinities and herbicidal
activity, they were found to be equipotent inhibitors of
IGPD2. The enantiopure compounds were then co-crystal-
lized with At IGPD2 DN construct B to produce structures at
1.15c and 1.5c resolution, for the S (PDB: 5EL9) and R
forms (PDB: 5ELW), respectively. The conformation of the
enzyme and the position of the metal ions were equivalent in
each complex, with the only clear difference, apart from the
inhibitor conformation, being minor changes in the solvent
structure within the active site (see Figure S5). In both
structures high quality electron density covered all the atoms
of the inhibitor (Figure 2b,c), thus confirming that the
additional difference features seen in the complexes with
the racemate arose as a result of mixed binding. The resulting
models show that for each chiral form of C348, the positions
of the phosphonate group, N2 and N4 of the triazole ring, and
the C2@OH substituent superimpose almost exactly andmake
equivalent interactions within the active site of the enzyme
(Figure 2d; see Figure S6a). This arrangement is achieved,
despite the inversion in chirality, by a combination of torsion-
angle changes around the C3@C2 and C2@C1 bonds of the
inhibitor, together with a difference in the tilt of the triazole
ring around the Mn1–Mn2 vector. The two enantiomers thus
trace an inverted path between the metal binding site and the
phosphonate binding site, whereby they are related by mirror-
image packing (Figure 3a,b). Both enantiomers retain low-
energy conformations with approximately staggered torsion
angles, with the largest deviation in the atomic position of
equivalent atoms occurring at C3 of the backbone, thus
explaining the weak density at this position observed in the
complexes of IGPD2 with the racemate.
Mirror-image packing of opposite enantiomers of ligands
to enzymes and receptors has been reported previously.
Examples include the binding of d/l-phenylalanine and the
superinhibitors d/l-2-aminooxy-3-phenylpropionic acid (d/l-
AOPP) to phenylalanine ammonia-lyase,[8] d/l-malate to
citrate synthase,[9] and d/l-isocitrate to isocitrate dehydrogen-
ase,[10] amongst others (see Figure S7).[11] In each of these
examples, and in the binding of the two enantiomers of C348
to IGPD, examination of the structures shows that the
position of three R groups around the chiral center is
approximately maintained on the enzyme surface by flipping
the direction of the hydrogen atom at the fourth position, by
1808, after inversion of chirality. This corresponds to the
approach of the free ligand to the enzyme surface in an
inverted configuration and generates a small separation in the
position of the chiral center of each enantiomer on either side
of the pseudo-mirror plane. Subtle changes to the dihedral
angles formed in the pendant groups optimize the fit within
Figure 2. Both enantiomers of C348 are equipotent inhibitors of
IGPD2. a) In vitro inhibition data for (R)-C348 (open circles) and (S)-
C348 (crosses) fit to log IC50 values of 2.62 and 2.84 (95% confidence
limits : log0.15, Hill coefficients of &0.8), respectively, and corre-
spond to Ki values of about (14:4) and (23:3) nm. Fitting was
carried out by nonlinear regression with equal weighting of data points
using GraphPad Prism (see Figure S3). Fo-Fc omit maps (gray mesh)
for the 1.4 b resolution (R)-C348 (white carbon atoms)/IGPD2 com-
plex structure (b) and the 1.1 b resolution (S)-C348 (teal carbon
atoms)/IGPD2 complex structure (c) contoured at 3 s. d) A super-
position of the structures of the two C348 enantiomers in complex
with IGPD2, thus showing how the active site can accommodate both
enantiomers of C348. A stereo view of the same image is provided in
Figure S6a.
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the chiral environment of the active site. On a case-by-case
basis, whether or not such a situation is feasible depends on
there being sufficient space to accommodate the two positions
of the chiral center and the new position of the fourth ligand
forming the chiral group (commonly a hydrogen atom). In
addition, the chemical nature of the pendant groups dictates
whether changes in the dihedral angles are energetically
accessible. Any small differences in geometry resulting from
the optimization of the fit to the active site will necessarily
give rise to a difference in the affinity of the two enantiomers,
but, as we show in IGPD, such differences can be remarkably
small and both enantiomers can act as highly potent
inhibitors.
As both enantiomers of C348 bind to At IGPD2, high-
resolution structures of Pyrococcus furiosus (Pf) IGPD (38%
sequence identity to At IGPD2) complexed with the enantio-
pure compounds (R : 1.8 c, PDB: 5DNX; S : 1.53c, PDB:
5DNL) were determined. These showed the same mode of
mirror-image packing as observed in At IGPD2 (see Fig-
ure S8), thus suggesting that the ability of IGPD to accom-
modate opposite chiral forms of C348 is a general feature of
the wider enzyme superfamily, rather than a peculiarity of the
Arabidopsis enzyme. We have previously proposed that
catalysis by IGPD involves conversion between an open
conformation of the enzyme, which binds to imidazole-IGP
(PDB: 4MU3), and a closed conformation, which binds
imidazolate–IGP (PDB: 4MU4), wherein a distinctly differ-
ent binding site for the substrate–phosphate moiety is
utilized.[7] Comparison of the open and closed At IGPD2/
substrate complexes with those of the At IGPD2/C348
complexes show that neither enantiomer of C348 can access
the phosphate binding site observed in the open enzyme/
substrate complex, as the backbone of the inhibitor is one
carbon atom shorter than that of the substrate. Rather, both
enantiomers of C348 utilize the phosphate binding site that is
associated with the closed conformation of the enzyme/
substrate complex, with the ordered C-loop; the conforma-
tion believed to be that adopted by the enzyme during
catalysis, thus suggesting that both enantiomers of C348 may
mimic reaction intermediates. During the reaction catalyzed
by IGPD, the adoption of an sp2 geometry at C3 is required
for the formation of the diazafulvene intermediate, a process
which is facilitated by the planar arrangement of the
imidazolate ring, C3 and C2 of imidazolate–IGP. The next
step in the reaction involves production of the D2-enol, which
also requires the adoption of an sp2 geometry at C2. This
geometry necessitates that C1 moves into the plane defined
by C3, C2 and the imidazolate (Figure 3c). Comparison of the
(R)- and (S)-C348 complexes with that of a modelled D2-enol
shows that the sp2 C2 of the D2-enol lies in approximately the
same position as that occupied by the sp3 C2 of both
enantiomers of C348. Moreover, the plane defined by the
main functional groups of C348 is the same as that occupied
by the modelled positions for the carbon backbone of the D2-
enol, and essentially bisects the positions of the R and S
enantiomers of the inhibitor (Figure 3d; see Figure S6b). This
position implies that the two enantiomers of C348 are
equipotent nanomolar inhibitors because a) the layout of
the enzyme active site facilitates mirror-image packing and
b) that they can both mimic the mode of binding of this
achiral reaction intermediate.
X-ray analysis is a powerful tool for studying the
molecular basis of how ligands are recognized by biological
macromolecules, but even when such studies are conducted at
high resolution, ligand density can sometimes be difficult to
interpret because of areas of weakness, the origins of which
are often difficult to explain and are commonly cited as
instances of disorder. In this study, weak electron density was
observed adjacent to the chiral center of the lead compound
in a 1.85c resolution structure of our target enzyme in
complex with a racemate. By extending the resolution and
chirally resolving the two enantiomers we confirmed that the
areas of weakness arose from the mirror-image packing of the
two enantiomers of the inhibitor in the active site, an
observation not without precedence. Without the high-
resolution data this important finding might have been
overlooked in IGPD2. Significantly, the mirror-image packing
of the two enantiomers of C348 in IGPD2 gives rise to
equipotency and, as in d/l-AOPP superinhibitors of phenyl-
alanine ammonia-lyase,[8] the mimicry of a reaction inter-
mediate gives rise to potent inhibition. This study adds to the
Figure 3. The equivalent planar arrangement of substituent groups in
(R)- and (S)-C348 generates a pseudo-mirror plane. a,b) The plane
(gray disk) was calculated in Chimera[1] based on the average positions
of the N2, N4, C2@OH, and C1@P bond positions for both enantio-
mers of C348, which are colored teal and white for the for the S and R
enantiomers, respectively. c) A model of the D2-enol (orange) in the
imidazole-IGP (yellow)/IGPD2 complex (PDB: 4MU4). The sp2 C2 of
the enol can be accommodated without altering the position of the
phosphate group. d) The modelled D2-enol bisects the positions of the
two enantiomers of C348.
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ever-growing body of evidence that certain enzymes are
chirally promiscuous and that mirror-image packing of ligands
is a more common feature than is generally recognized in the
field of drug development. Whilst the future challenge with
IGPD is to exploit this understanding for the development of
novel herbicides, our findings may also be relevant in other
areas of drug discovery where the potential to develop
inhibitors with opposite chirality may have been overlooked.
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